[go: up one dir, main page]

ITMI20002358A0 - Derivati di tieno [2,3-c]isochinolin-3-one come inibitori della poli(adp-ribosio)polimerasi - Google Patents

Derivati di tieno [2,3-c]isochinolin-3-one come inibitori della poli(adp-ribosio)polimerasi

Info

Publication number
ITMI20002358A0
ITMI20002358A0 IT2000MI002358A ITMI20002358A ITMI20002358A0 IT MI20002358 A0 ITMI20002358 A0 IT MI20002358A0 IT 2000MI002358 A IT2000MI002358 A IT 2000MI002358A IT MI20002358 A ITMI20002358 A IT MI20002358A IT MI20002358 A0 ITMI20002358 A0 IT MI20002358A0
Authority
IT
Italy
Prior art keywords
isoquinolin
thieno
adp
ribose
poly
Prior art date
Application number
IT2000MI002358A
Other languages
English (en)
Inventor
Roberto Pellicciari
Flavio Moroni
Original Assignee
Roberto Pellicciari
Flavio Moroni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Pellicciari, Flavio Moroni filed Critical Roberto Pellicciari
Priority to IT002358A priority Critical patent/ITMI20002358A1/it
Publication of ITMI20002358A0 publication Critical patent/ITMI20002358A0/it
Priority to AU2002212575A priority patent/AU2002212575A1/en
Priority to US10/415,601 priority patent/US6989388B2/en
Priority to DE60140086T priority patent/DE60140086D1/de
Priority to EP04076527A priority patent/EP1464646B1/en
Priority to AT04076527T priority patent/ATE444298T1/de
Priority to ES04076527T priority patent/ES2332588T3/es
Priority to PCT/IB2001/002030 priority patent/WO2002036599A1/en
Priority to JP2002539357A priority patent/JP4417622B2/ja
Priority to EP01980788A priority patent/EP1332147A1/en
Publication of ITMI20002358A1 publication Critical patent/ITMI20002358A1/it
Priority to US11/264,468 priority patent/US7825129B2/en
Priority to US12/938,163 priority patent/US20110237617A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT002358A 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi ITMI20002358A1 (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
EP01980788A EP1332147A1 (en) 2000-10-31 2001-10-30 Thieno[2,3-c isoquinolines for use as inhibitors of parp
EP04076527A EP1464646B1 (en) 2000-10-31 2001-10-30 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp
US10/415,601 US6989388B2 (en) 2000-10-31 2001-10-30 Thieno[2,3-c]iosquinolines for use as inhibitors of PARP
DE60140086T DE60140086D1 (de) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolinen zur Verwendung als Parp-Inhibitoren
AU2002212575A AU2002212575A1 (en) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolines for use as inhibitors of parp
AT04076527T ATE444298T1 (de) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolinen zur verwendung als parp-inhibitoren
ES04076527T ES2332588T3 (es) 2000-10-31 2001-10-30 Tieno(2,3-c)isoquinolinas para usar como inhibidores de parp.
PCT/IB2001/002030 WO2002036599A1 (en) 2000-10-31 2001-10-30 Thieno[2,3-c]isoquinolines for use as inhibitors of parp
JP2002539357A JP4417622B2 (ja) 2000-10-31 2001-10-30 Ｐａｒｐの阻害剤として用いるためのチエノ［２，３−ｃ］イソキノリン
US11/264,468 US7825129B2 (en) 2000-10-31 2005-11-01 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP
US12/938,163 US20110237617A1 (en) 2000-10-31 2010-11-02 Thieno[2,3-c] isoquinolines for use as inhibitors of parp

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Publications (2)

Publication Number Publication Date
ITMI20002358A0 true ITMI20002358A0 (it) 2000-10-31
ITMI20002358A1 ITMI20002358A1 (it) 2002-05-01

Family

ID=11446071

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Country Status (9)

Country Link
US (3) US6989388B2 (it)
EP (2) EP1464646B1 (it)
JP (1) JP4417622B2 (it)
AT (1) ATE444298T1 (it)
AU (1) AU2002212575A1 (it)
DE (1) DE60140086D1 (it)
ES (1) ES2332588T3 (it)
IT (1) ITMI20002358A1 (it)
WO (1) WO2002036599A1 (it)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EA011211B1 (ru) 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
JP4864718B2 (ja) * 2003-11-20 2012-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての６−アルケニルおよび６−フェニルアルキル置換２−キノリノンおよび２−キノキサリノン
EP1687277B1 (en) * 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
EP1771175B1 (en) 2004-06-30 2015-12-23 Janssen Pharmaceutica NV Phthalazine derivatives as parp inhibitors
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2008030891A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
US8275635B2 (en) * 2007-02-16 2012-09-25 Bodymedia, Inc. Integration of lifeotypes with devices and systems
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
WO2009047752A1 (en) 2007-10-09 2009-04-16 Ramot At Tel-Aviv University Ltd. Breast cancer therapy
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
JP5525447B2 (ja) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
EP2217244A4 (en) * 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
JP2011506343A (ja) * 2007-12-07 2011-03-03 バイパー サイエンシズ，インコーポレイティド トポイソメラーゼ阻害剤とｐａｒｐ阻害剤との組み合わせによるがんの治療
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
ATE513818T1 (de) 2008-03-27 2011-07-15 Janssen Pharmaceutica Nv Chinazolinonderivate als tubulinpolymerisationshemmer
SI2271626T1 (sl) 2008-03-27 2015-03-31 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
SA109300394B1 (ar) 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
CA2728466A1 (en) * 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
AU2013209394A1 (en) 2012-01-20 2014-08-28 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
JP2020500214A (ja) 2016-11-02 2020-01-09 イミュノジェン・インコーポレーテッド 抗体薬物複合体とｐａｒｐ阻害剤との併用治療
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021108350A1 (en) 2019-11-25 2021-06-03 The Research Foundation For The State University Of New York Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US6358975B1 (en) * 1997-08-15 2002-03-19 Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
AU9298798A (en) * 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Also Published As

Publication number Publication date
ITMI20002358A1 (it) 2002-05-01
EP1464646A1 (en) 2004-10-06
JP4417622B2 (ja) 2010-02-17
AU2002212575A1 (en) 2002-05-15
EP1332147A1 (en) 2003-08-06
WO2002036599A1 (en) 2002-05-10
US6989388B2 (en) 2006-01-24
JP2004520273A (ja) 2004-07-08
DE60140086D1 (de) 2009-11-12
US7825129B2 (en) 2010-11-02
US20110237617A1 (en) 2011-09-29
ATE444298T1 (de) 2009-10-15
US20060094746A1 (en) 2006-05-04
EP1464646B1 (en) 2009-09-30
US20040082789A1 (en) 2004-04-29
ES2332588T3 (es) 2010-02-09

Similar Documents

Publication Publication Date Title
ITMI20002358A0 (it) Derivati di tieno [2,3-c]isochinolin-3-one come inibitori della poli(adp-ribosio)polimerasi
NO20051928D0 (no) Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.
MA25876A1 (fr) Inhibiteurs tricycliques de poly (adp-ribose) polymerases
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
AU2002214505A1 (en) New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
ATE372988T1 (de) Pyrimidin-derivate
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
MA26060A1 (fr) Nouveaux derives de pyrazolopyridine
AU2002333524A1 (en) Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
IS6443A (is) Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar
MXPA03004262A (es) Derivados de (dihidro)isoquinolina como inhibidores de fosfodiesterasa.
NO20023770L (no) Indol-3-ylderivater
ATE519761T1 (de) 5-aminoalkyl-pyrazoloä4,3-düpyrimidine mit phosphodiesterase v inhibierender wirkung
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
MA26967A1 (fr) Derives de pyrimidine
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
ATE258935T1 (de) Furo(3,2-b)pyridine als 5-ht1f agonisten
NO20035206D0 (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
IT1313592B1 (it) Derivati di 1h-pirido 3,4-b indol-1-one.
DK1259515T3 (da) Thienopyridinderivater og deres anvendelse som antiinflammatoriske midler
IS7042A (is) (Pýridó/þíenó)-[f]-oxasepín-5-on afleiður
AU2001293825A1 (en) Hollow block